Bayer Aktiengesellschaft (BAYRY)
OTCMKTS · Delayed Price · Currency is USD
13.16
+0.36 (2.81%)
Oct 29, 2026, 11:42 AM EDT
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 10.87B EUR in the quarter ending June 30, 2026, with 1.24% growth. This brings the company's total for the last twelve months to 45.38B, down -1.73% year-over-year. In the year 2025, Bayer Aktiengesellschaft had annual revenue of 45.58B, down -2.21%.
Revenue (ttm)
45.38B EUR
Revenue Growth
-1.73%
P/S Ratio
0.97
Revenue / Employee
516.62K EUR
Employees
87,830
Market Cap
51.82B USD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Bayer Aktiengesellschaft breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.58B | -1.03B | -2.21% |
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | 43.55B | 6.80B | 18.52% |
| Dec 31, 2018 | 36.74B | 1.73B | 4.93% |
| Dec 31, 2017 | 35.02B | 72.00M | 0.21% |
| Dec 31, 2016 | 34.94B | -11.14B | -24.18% |
| Dec 31, 2015 | 46.09B | 4.75B | 11.48% |
| Dec 31, 2014 | 41.34B | 1.18B | 2.94% |
| Dec 31, 2013 | 40.16B | 416.00M | 1.05% |
| Dec 31, 2012 | 39.74B | 3.21B | 8.80% |
| Dec 31, 2011 | 36.53B | 1.44B | 4.10% |
| Dec 31, 2010 | 35.09B | 3.92B | 12.58% |
| Dec 31, 2009 | 31.17B | -1.75B | -5.32% |
| Dec 31, 2008 | 32.92B | 533.00M | 1.65% |
| Dec 31, 2007 | 32.39B | 3.43B | 11.84% |
| Dec 31, 2006 | 28.96B | 4.26B | 17.23% |
| Dec 31, 2005 | 24.70B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 594.41M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 141.01M |
| Northwest Biotherapeutics | 2.17M |
| Silence Therapeutics | 615.00K |
| Comjoyful International Company | 564.97K |
Bayer Aktiengesellschaft News
- 3 days ago - China approves Bayer blood thinner asundexian - Reuters
- 3 days ago - Bayer Gets in China Its First Global Approval for Stroke Prevention Drug - WSJ
- 5 days ago - ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence - Business Wire
- 20 days ago - Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting - Business Wire
- 21 days ago - Bayer partners with actress Melissa Joan Hart to increase awareness of Lynkuet - TheFly
- 21 days ago - Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause - Business Wire
- 21 days ago - Bayer announces FDA acceptance of Kerendia sNDA - TheFly
- 21 days ago - U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes - Business Wire